Loss of FHIT expression in acute lymphoblastic leukemia.

Loss of expression of the FHIT tumor suppressor gene is common in epithelial malignancies such as lung, kidney, esophageal, gastric, and cervical cancers. To assess the role of FHIT in acute leukemias, we examined 18 primary acute lymphoblastic leukemias (ALLs), 8 ALL-derived cell lines, 7 cell lines from other hematological malignancies, 14 lymphoblastoid cell lines, and 5 peripheral blood lymphocyte samples for expression of FHIT mRNA and protein by reverse transcription-PCR and Northern and Western blots. Fhit protein expression was detected in only 24% of primary ALLs and leukemia/lymphoma cell lines, but it was detected in all lymphoblastoid cell lines and peripheral blood lymphocyte samples. Interestingly, Fhit protein expression was lost in all T-cell ALLs but was lost in only half of the B-cell ALLs. Northern blotting of 7 normal lymphoblastoid cell lines and 13 of the neoplastic cell lines confirmed the results obtained by Western blotting regarding FHIT expression. The high frequency of loss of Fhit expression in ALLs suggests that inactivating alterations at the FHIT locus contribute to development of the leukemias.

[1]  M. Tschan,et al.  Aberrant FHIT mRNA transcripts are present in malignant and normal haematopoiesis, but absence of FHIT protein is restricted to leukaemia , 1999, Oncogene.

[2]  M. Rugge,et al.  Loss of FHIT expression in gastric carcinoma. , 1998, Cancer research.

[3]  L. Cannizzaro,et al.  FHIT gene transcript alterations occur frequently in myeloproliferative and myelodysplastic diseases , 1998, Cytogenetic and Genome Research.

[4]  R. Aguiar,et al.  Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. , 1998, British Journal of Cancer.

[5]  Y. Pekarsky,et al.  Absence or reduction of Fhit expression in most clear cell renal carcinomas. , 1998, Cancer research.

[6]  D. Christiani,et al.  Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. , 1998, Cancer research.

[7]  B. Simon,et al.  Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. , 1998, Cancer research.

[8]  Jan-Gowth Chang,et al.  Analysis of FHIT transcripts in cervical and endometrial cancers , 1998, International journal of cancer.

[9]  O. Cussenot,et al.  Molecular analysis of the FHIT gene in human prostate cancer , 1998, Oncogene.

[10]  P. H. Chen,et al.  Aberrant FHIT transcripts in hepatocellular carcinomas. , 1998, British Journal of Cancer.

[11]  C. Shen,et al.  HPV‐associated cervical cancers show frequent allelic loss at 3p14 but no apparent aberration of FHIT mRNA , 1998, International journal of cancer.

[12]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  C. Croce,et al.  Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. , 1997, Cancer research.

[14]  T. Goodrow,et al.  The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down-regulated in kidney cancers. , 1997, The American journal of pathology.

[15]  J. Chang,et al.  Aberrant FHIT transcripts in acute myeloid leukaemia , 1997, British journal of haematology.

[16]  Kathleen R. Cho,et al.  Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. , 1997, Cancer research.

[17]  Stanley N Cohen,et al.  Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours , 1997, Oncogene.

[18]  D. Beer,et al.  Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas , 1997, Oncogene.

[19]  F. Mitelman,et al.  Variable FHIT transcripts in non‐neoplastic tissues , 1997 .

[20]  S. Naylor,et al.  Normal FHIT transcripts in renal cell cancer‐ and lung cancer‐derived cell lines, including a cell line with a homozygous deletion in the FRA3B region , 1997, Genes, chromosomes & cancer.

[21]  G. Giaccone,et al.  FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. , 1997, Cancer research.

[22]  M. Birrer,et al.  FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. , 1997, Cancer research.

[23]  K. Miyagawa,et al.  Decreased or Altered Expression of the FHIT Gene in Human Leukemias , 1997, Stem cells.

[24]  C. Croce,et al.  Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. , 1997, Cancer research.

[25]  C. Croce,et al.  Structure and expression of the human FHIT gene in normal and tumor cells. , 1997, Cancer research.

[26]  H. Klinger,et al.  Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. , 1997, Human molecular genetics.

[27]  L. D. Barnes,et al.  Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase. , 1996, Biochemistry.

[28]  C. Croce,et al.  FHIT gene alterations in head and neck squamous cell carcinomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Croce,et al.  The FHIT gene at 3p14.2 is abnormal in breast carcinomas. , 1996, Cancer research.

[30]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[31]  M. Rugge,et al.  Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. , 1996, Cancer research.

[32]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[33]  T. Glover,et al.  FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. , 1996, Human molecular genetics.

[34]  G. Huez,et al.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. , 1995, Blood.

[35]  D. Jong,et al.  Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. , 1995, Blood.

[36]  S. Knuutila,et al.  Cloning and characterization of the human t(3;6)(p14;p11) translocation breakpoint associated with hematologic malignancies. , 1993, Cancer genetics and cytogenetics.

[37]  K. Tanaka,et al.  Loss of heterozygosity at D3S2 locus of short arm of chromosome 3 in chronic myelogenous leukemia. , 1992, Cancer genetics and cytogenetics.

[38]  C. Croce,et al.  FHIT in human cancer. , 1998, Advances in cancer research.